Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

43%

3 of 7 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT01313351Completed

RPS InflammaDry Detector™ to Determine MMP-9 Levels in Tears

Role: lead

NCT02018198Completed

FebriDx DISRUPT Acute Respiratory Infection Trial in Acute Respiratory Infection: An Evaluation of FebriDx® POC Test

Role: lead

NCT05403346Terminated

Clinical Evaluation of a COVID-19 Antigen Self-Test (CoviDx™)

Role: collaborator

NCT00921895Not ApplicableCompleted

A Comparison of the RPS Adeno Detector IV to Viral Cell Culture at Detecting Adenoviral Conjunctivitis

Role: lead

NCT04699903Completed

Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood

Role: collaborator

NCT04750629Completed

Clinical Evaluation of a Point-of-Care (POC), COVID-19 Rapid Antigen Test (CoviDx™)

Role: collaborator

NCT01692964Completed

Clinical Evaluation of the InflammaDry Device for Detecting Dry Eye

Role: lead

NCT00266734Not ApplicableCompleted

Evaluation of a Rapid Screening Test for Detection of Adenovirus in Tears

Role: lead

All 8 trials loaded